Analysis of alpha-synuclein in malignant melanoma - Development of a SRM quantification assay

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Welinder, Charlotte ^a   Jönsson, Göran B ^a   Ingvar, Christian ^a,b   Lundgren, Lotta ^a,b   Baldetorp, Bo ^a   Olsson, Håkan ^a,b   Breslin, Thomas ^c   Rezeli, Melinda ^a   Jansson, Bo ^a   Fehniger, Thomas E ^a   Laurell, Thomas ^a,c   Wieslander, Elisabet ^a   Pawlowski, Krzysztof ^a,d   Marko Varga, György ^a,c,e  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; HEMOGLOBIN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CALIBRATION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HEMOGLOBIN ANALYSIS; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MELANOMA; MICROARRAY ANALYSIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATIENT IDENTIFICATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SELECTED REACTION MONITORING QUANTIFICATION ASSAY; SEQUENCE ANALYSIS; SNCA GENE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; VERY ELDERLY; ANTIBODY SPECIFICITY; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PATHOLOGY; PROGNOSIS; PROTEOMICS;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; ORGAN SPECIFICITY; PROGNOSIS; PROTEOMICS; RNA, MESSENGER;

EID: 84908191937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110804     Document Type: Article

References (54)

1. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355: 51-65.
2. McInnes J (2013) Insights on altered mitochondrial function and dynamics in the pathogenesis of neurodegeneration. Transl Neurodegener 2: 12.
3. Rochet JC, Hay BA, Guo M (2012) Molecular insights into Parkinson's disease. Prog Mol Biol Transl Sci 107: 125-188.
4. Waxman EA, Giasson BI (2009) Molecular mechanisms of α-synuclein neurodegeneration. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1792: 616-624.
5. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, et al. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14: 467-475.
6. George S, Rey NL, Reichenbach N, Steiner JA, Brundin P (2013) α-Synuclein: The Long Distance Runner. Brain Pathology 23: 350-357.
7. Matsuo Y, Kamitani T (2010) Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One 5: e10481.
8. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, et al. (2008) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21: 665-676.
9. Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, et al. (2011) Molecular Network Associated with MITF in Skin Melanoma Development and Progression. J Skin Cancer 2011: 730170.
10. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
11. Tabares-Seisdedos R, Rubenstein JL (2013) Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci 14: 293-304.
12. Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, et al. (2010) Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 67: 347-352.
13. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A (2009) Family history of melanoma and Parkinson disease risk. Neurology 73: 1286-1291.
14. Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17: 582-587.
15. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, et al. (2005) Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 92: 201-205.
16. Cookson MR (2009) alpha-Synuclein and neuronal cell death. Mol Neurodegener 4: 9.
17. Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE (2013) α-Synuclein oligomers and clinical implications for Parkinson disease. Annals of Neurology 73: 155-169.
18. McGlinchey RP, Yap TL, Lee JC (2011) The yin and yang of amyloid: insights from [small alpha]-synuclein and repeat domain of Pmel17. Physical Chemistry Chemical Physics 13: 20066-20075.
19. Paisan-Ruiz C, Houlden H (2010) Common pathogenic pathways in melanoma and Parkinson disease. Neurology 75: 1653-1655.
20. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, et al. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090-3099.
21. Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG (2005) Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 118: 3523-3530.
22. Slominski A, Tobin DJ, Shibahara S, Wortsman J (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155-1228.
23. Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S (2007) Treatment with levodopa and risk for malignant melanoma. Mov Disord 22: 1252-1257.
24. Schmid AW, Fauvet B, Moniatte M, Lashuel HA (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson's disease and other synucleinopathies. Mol Cell Proteomics.
25. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315-325.
26. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, et al. (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10: 230-240.
27. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, et al. (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133: 713-726.
28. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, et al. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349: 162-166.
29. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, et al. (2010) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75: 1766-1772.
30. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, et al. (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders - a marker of synapse loss? Neurosci Lett 450: 332-335.
31. Beyer K (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol 112: 237-251.
32. Schmid AW, Fauvet B, Moniatte M, Lashuel HA (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson's disease and other synucleinopathies. Molecular & Cellular Proteomics.
33. Bonini NM, Giasson BI (2005) Snaring the function of alpha-synuclein. Cell 123: 359-361.
34. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383-396.
35. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, et al. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329: 1663-1667.
36. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324-328.
37. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, et al. (2002) Tubulin seeds alpha-synuclein fibril formation. J Biol Chem 277: 2112-2117.
38. Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, et al. (2004) Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J Alzheimers Dis 6: 435-442; discussion 443-439.
39. Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, et al. (2012) ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res 40: W597-603.
40. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. Journal of Molecular Biology 215.
41. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, et al. (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26: 966-968.
42. Campbell J, Rezai T, Prakash A, Krastins B, Dayon L, et al. (2011) Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. Proteomics 11: 1148-1152.
43. Picotti P, Rinner O, Stallmach R, Dautel F, Farrah T, et al. (2010) High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods 7: 43-46.
44. Deutsch EW, Lam H, Aebersold R (2008) PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep 9: 429-434.
45. Picotti P, Aebersold R (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 9: 555-566.
46. Chace DH, Barr JR, Duncan MW, Matern D, Morris MR, et al. (2006) Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline. Clinical and Laboratory Standards Institute, Wayne, PA.
47. Kitchen S, Jennings I, Woods T, Kitchen D, Walker I, et al. (2006) Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 32: 492-498.
48. Wirdefeldt K, Weibull CE, Chen H, Kamel F, Lundholm C, et al. (2013) Parkinson's Disease and Cancer: A Register-based Family Study. American Journal of Epidemiology.
49. McLean JR, Hallett PJ, Cooper O, Stanley M, Isacson O (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci 49: 230-239.
50. McLean PJ, Hyman BT (2002) An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neurosci Lett 323: 219-223.
51. Takahashi T, Yamashita H, Nakamura T, Nagano Y, Nakamura S (2002) Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res 938: 73-80.
52. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al. (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5: 55-59.
53. Kasuga K, Nishizawa M, Ikeuchi T (2012) alpha-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. Int J Alzheimers Dis 2012: 437025.
54. Welinder C, Jonsson G, Ingvar C, Lundgren L, Baldetorp B, et al. (2014) Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification. J Proteome Res 13: 1315-1326.